Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Colon Capsule Endoscopy (CCE) Versus Computed Tomographic Colonography (CTC) in the Identification of Colonic Polyps in a Screening Population. (TOPAZ)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02754661
Recruitment Status : Completed
First Posted : April 28, 2016
Results First Posted : October 1, 2019
Last Update Posted : October 1, 2019
Sponsor:
Information provided by (Responsible Party):
Medtronic - MITG

Brief Summary:
The primary objective of this multicenter, prospective, randomized study is to assess the diagnostic yield of Colon Capsule Endoscopy (CCE) versus Computed Tomographic Colonography (CTC) in a screening population.

Condition or disease Intervention/treatment Phase
Colorectal Cancer Screening Device: COLON Capsule endoscopy Device: Computed Tomographic Colonography Not Applicable

Detailed Description:

This is a multicenter, prospective, randomized study to evaluate the efficacy of CCE versus CTC in the identification of colonic polyps in a screening population.

Subjects will be enrolled at up to 20 clinical sites in the United States. Subjects who meet the eligibility criteria will be screened by the gastroenterology site for study participation at a baseline visit which will also include a blood test for renal function (eGFR), and will be evaluated on the randomized procedure day (CCE versus CTC) and again on the day of both the blinded and unblinded OC procedures. Telephone follow-ups will be conducted 5 - 9 days after the CCE/CTC procedure and 5 - 9 days after the unblinded OC procedure to assess subject well-being and capture any Adverse Events (AEs), regardless of relationship to the CCE, CTC, or Optical colonoscopy (OC) procedures.

All CCE RAPID® videos and CTC images will be evaluated by local and central readers. All study analyses will be based on central reader results for both CCE and CTC. Two sets of central readers will be utilized, one set for reading of the CCE RAPID® videos and one set for reading the CTC studies. Both groups of readers will be experts in the reading process for their respective procedures. Readers will provide a report of their findings to the sponsor within 2 weeks of capsule ingestion or CTC procedure in order to allow subjects to return within 5 weeks capsule ingestion or CTC procedure to undergo confirmatory OC. The first OC procedure will be performed with the clinician blinded to the CCE or CTC results. Immediately following this blinded procedure, the clinician will review the CCE or CTC results report provided by the sponsor from the central readers, and a second unblinded OC procedure will be performed if there are discrepancies between the CCE/CTC findings and OC.

Colonoscopy must not be performed by the same person who conducts the local CCE reading, or anyone who has reviewed CCE/CTC results for that subject.

Bowel preparation regimens for all three procedure types will be standardized across sites.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 320 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Multicenter, Prospective, Randomized Study Comparing the Diagnostic Yield of Colon Capsule Endoscopy Versus Computed Tomographic Colonography in a Screening Population
Study Start Date : September 2016
Actual Primary Completion Date : August 7, 2018
Actual Study Completion Date : August 7, 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: COLON Capsule endoscopy

Subjects will be instructed to follow a detailed dietary and colon preparation regimen prior to and during the CCE procedure day. With the exception of Gastrografin, all colon preparation products will be standard colon cleansing products approved by the FDA.

Between 45 and 75 minutes after the final Polyethylene Glycol (PEG) ingestion, the subject will swallow the PillCam COLON Capsule with a cup of water.

If necessary, capsule position will be monitored to ensure adequate booster administration. Subjects will keep a timed diary of key preparation steps and bowel activity, including capsule excretion. Subjects will be allowed to leave the unit 10 hours after capsule ingestion if the capsule is not yet excreted. Subjects leaving before excretion will be instructed to disconnect the recorder at excretion or 12 hours after capsule ingestion (whichever comes first).

Device: COLON Capsule endoscopy
Active Comparator: Computed Tomographic Colonography

Subjects will be instructed to follow a detailed dietary and colon preparation regimen prior to and during the Computed Tomographic Colonography (CTC) procedure day.

The CTC procedure and study interpretation will be conducted in accordance with the ACR-SAR-SCBT-MR Practice Parameter for the Performance of CT Colonography in Adults. Colon insufflation will be performed with the subject in the lateral decubitus or supine position.With the subject in the supine position, a CT scout image will be taken to confirm adequate colon distention. If adequate bowel distention is not achieved, additional air will be insufflated into the colon. After scanning the subject in the supine position, the subject will be placed in the prone position, and additional CO2 will be administered. Subsequently, CT will be performed with the subject in the prone position. If a prone position is not possible for the subject, a left lateral decubitus position is preferred for optimal gas and fluid redistribution.

Device: Computed Tomographic Colonography



Primary Outcome Measures :
  1. Number of Participants With an Actionable Lesion on CCE vs. CTC Confirmed by Optical Colonoscopy [ Time Frame: 5-6 weeks from randomized procedure ]

    Proportion of subjects shown to have an actionable lesion, defined as any polyp or mass lesion ≥6 mm.

    Diagnostic yield of CCE/CTC will be calculated in relation to the confirmatory Optical colonoscopy results



Secondary Outcome Measures :
  1. Sensitivity of CCE Versus CTC in the Detection of Polyps ≥6 mm [ Time Frame: 5-6 weeks from randomized procedure ]
    Sensitivity (the percentage of patients with disease who test positive) assessed in relation to the confirmatory optical colonoscopy (OC) results on a "per subject" basis

  2. Specificity of CCE Versus CTC in the Detection of Polyps ≥6 mm [ Time Frame: 5-6 weeks from randomized procedure ]
    Specificity (the percentage of patients without disease who test negative) assessed in relation to the confirmatory optical colonoscopy (OC) results on a "per subject" basis

  3. Predictive Value of a Positive Test (PPV) of CCE Versus CTC in the Detection of Polyps ≥6 mm [ Time Frame: 5-6 weeks from randomized procedure ]
    Predictive value of a positive test (PPV) is the percentage of patients with positive tests who have disease assessed in relation to the confirmatory OC results on a "per subject" basis

  4. Predictive Value of a Negative (NPV) of CCE Versus CTC in the Detection of Polyps ≥6 mm [ Time Frame: 5-6 weeks from randomized procedure ]
    Predictive value of a negative test (NPV) is the percentage of patients with negative tests who do not have disease, assessed in relation to the confirmatory OC results on a "per subject" basis.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   50 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Subject is between 50 and 75 years of age (for African Americans only, subject is between 45-75 years of age).
  2. Subject is classified as average risk per the American Gastroenterological Association Guidelines on Colorectal Cancer Screening: Individuals without a personal or family history of CRC or adenomas, inflammatory bowel disease, or high-risk genetic syndromes.
  3. Subject is willing and able to participate in the study procedures and to understand and sign the informed consent.

Exclusion Criteria:

  1. Subject with history of colorectal cancer or adenoma (including those identified by computed tomography [CT], optical colonoscopy [OC[, sigmoidoscopy, etc.).
  2. Subject with history of negative colonoscopy within 10 years, as these subjects would be defined as not requiring screening in this timeframe. For subjects with alternative screening methods, refer to applicable guidelines.
  3. Subject with currently suspected or diagnosed with hematochezia, melena, iron deficiency with or without anemia, or any other rectal bleeding, including positive fecal occult blood test of any variety.
  4. Subject with any current condition believed to have an increased risk of capsule retention such as suspected or known bowel obstruction, stricture, or fistula.
  5. Subject with current dysphagia or any swallowing disorder.
  6. Subject with current serious medical conditions that would increase the risk associated with CCE, CTC, or colonoscopy that are so severe that screening would have no benefit.
  7. Subject with a cardiac pacemaker or other implanted electromedical device.
  8. Subject expected to undergo MRI examination within 7 days after ingestion of the capsule.
  9. Subject with clinical evidence of renal disease, including clinically significant laboratory abnormalities of renal function within the past 6 months, or at any time in the past if not tested within the last 6 months, defined as creatinine, blood urea nitrogen (BUN), and/or glomerular filtration rate (GFR) outside of the local laboratory reference range.
  10. Subject with a diagnosis of gastroparesis or small bowel or large bowel dysmotility.
  11. Subject with allergies or known contraindication to the medications or preparation agents used in the procedure as described in the relevant instructions for use.
  12. Subject has an estimated life expectancy of less than 6 months.
  13. Subject is considered to be part of a vulnerable population (e.g. prisoners or those without sufficient mental capacity).
  14. Subject is pregnant, suspected pregnant, or is actively breast-feeding. Females of child-bearing potential will be required to provide either a urine pregnancy test or serum pregnancy test as part of the participant's standard of care regardless of their participation in the study (except for subjects who are surgically sterile or are post-menopausal for at least two years).
  15. Subject has participated in an investigational drug or device research study within 30 days of enrollment that may interfere with the subject's safety or ability to participate in this study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02754661


Locations
Layout table for location information
United States, Alabama
University of South Alabama
Mobile, Alabama, United States, 36688
United States, Florida
Borland-Groover Clinic
Jacksonville, Florida, United States, 32256
United States, Illinois
Loyola University Medical Center
Chicago, Illinois, United States, 60153
United States, Indiana
Indiana University Hospital
Indianapolis, Indiana, United States, 46202
Indianapolis Gastroenterology and Hepatology
Indianapolis, Indiana, United States, 46237
United States, Massachusetts
Baystate Hospital
Springfield, Massachusetts, United States, 01199
United States, Minnesota
Mayo Clinic Rochester
Rochester, Minnesota, United States, 55905
United States, Missouri
Clinical Research Professionals
Saint Louis, Missouri, United States, 63141
United States, New York
NYU
New York, New York, United States, 10016
Columbia University
New York, New York, United States, 10032
United States, North Carolina
Asheville Gastroenterology Associates
Asheville, North Carolina, United States, 28801
United States, Pennsylvania
Thomas Jefferson University
Philadelphia, Pennsylvania, United States, 19107
United States, Virginia
Virginia Gastroenterology institute
Suffolk, Virginia, United States, 23434
Sponsors and Collaborators
Medtronic - MITG
Investigators
Layout table for investigator information
Principal Investigator: Brooks Cash, MD University of South Alabama
  Study Documents (Full-Text)

Documents provided by Medtronic - MITG:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Medtronic - MITG
ClinicalTrials.gov Identifier: NCT02754661    
Other Study ID Numbers: COVGIC20543
MA-213 ( Other Identifier: Medtronic )
First Posted: April 28, 2016    Key Record Dates
Results First Posted: October 1, 2019
Last Update Posted: October 1, 2019
Last Verified: August 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Medtronic - MITG:
Polyps; Capsule endoscopy; CT Colonography; Colonoscopy; Average risk patients for colorectal cancer screening
Additional relevant MeSH terms:
Layout table for MeSH terms
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases